TRIM29 and breast carcinoma: Additionally, data from Clinical Proteomic Tumor Analysis Consortium revealed that most subtypes of TNBC, except for the LAR subtype, exhibited an increased protein expression of TRIM29 compared to Luminal and HER2-enriched breast cancer (Fig. 1G, H).